Vusolimogene Oderparepvec not checked

Replimune, Inc. · RP1

FollowEvery change as it happens, and a Monday email
Next date
Phase 2 trial completes
Trials
5 active
6 in total · 5 in the EU
Targets
—
None known yet

What this is

How it works
A gene therapy: delivers a gene into the patient's cells so they make a protein they lack.-gene: gene therapy substances WHO name stem
Tested for
Advanced Melanoma, Cutaneous Squamous Cell Carcinoma, Advanced Cutaneous Squamous Cell Carcinoma, Metastatic Cutaneous Squamous Cell Carcinoma, Non-Small Cell Lung Cancer (NSCLC), Microsatellite Instability-High (MSI-H), Non-melanoma Skin Cancer (NMSC), Cutaneous Melanoma and 4 more
Main trialPhase 3
“This is a randomized, controlled, multicenter, open-label Phase 3 clinical study comparing VO in combination with nivolumab versus Physician's Choice treatment for patients with unresectable Stage IIIb-IV cutaneous melanoma whose disease progressed on an anti PD-1 and an anti-CTLA-4 containing regimen (administered either as a combination regimen or in sequence) or who are not candidates for treatment with an anti-CTLA-4 therapy.”In the company’s words, NCT06264180 on ClinicalTrials.gov
Other names
RP1 · VO

Other drugs for Advanced Melanoma

All 196 drugs for Advanced Melanoma

Coming up3

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials6

TrialPhaseCompletesWhat it tests
Phase 3Recruiting 30 Sep 2030 VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
Phase 2Active, not recruiting Sep 2025 Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer
Phase 2Active, not recruiting Jun 2028 Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)
Phase 1/2Active, not recruiting Jul 2029 Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies
Phase 2Ended not given "neoBREASTIM": A Phase 2 Study of Atezolizumab plus RP1 oncolytic immunotherapy in the NeoAdjuvant setting of Triple-Negative Breast Cancer (TNBC)
Phase 4Authorised not given Long-term Safety Outcomes in Patients Treated With Replimune Oncolytic Immunotherapy Products
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Vusolimogene Oderparepvec

Following is part of Solo: you see every change to Vusolimogene Oderparepvec the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in